XCancer

Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes

Description:

\[18F\]F-PDL1-3 molecular probe was used to detect the expression of PD-L1 in primary and metastatic tumors of patients with solid tumors. The heterogeneity of PD-L1 expression in the same lesion and different lesions was further evaluated, and the changes of PD-L1 expression in the course of the disease were observed. This method is helpful for the screening of patients with solid tumors with high PD-L1 expression, efficacy monitoring, and early warning of drug resistance and/or recurrence or metastasis, and ultimately achieve individualized targeted therapy of tumors

Sponsor:

Peking University Cancer Hospital & Institute

Phase:

Phase 2

Contacts:

Hua Zhu (PRINCIPAL_INVESTIGATOR)

Hua Zhu (CONTACT)

zhuhuabch@pku.edu.cn

010-88196495

Government Study Link:

NCT07848243 - Click here to see study on

ClinicalTrials.gov

FDG

Isotope(s):
Target(s):
  • Glucose Transport
Ligand Class: Small Molecules

PDL1-3

Isotope(s):
Target(s):
  • PD-L1
Ligand Class: Small Molecules
Inclusion
  • subjects with pathologically confirmed solid tumors (lung cancer, cervical cancer, melanoma, breast cancer, gastrointestinal tumor, etc.), recent recurrence or suspected recurrence of previous solid tumors;
  • There was at least one measurable target lesion according to RECIST1.1 criteria;
  • Blood routine, liver and kidney function meet the following standards: see the study protocol for specific requirements;
Exclusion
  • Severe abnormal liver and kidney function.
  • Unable to lie flat for half an hour.
  • Claustrophobia or other mental illness.